RT Journal Article SR Electronic T1 A New Era of Clinical Dopamine Transporter Imaging Using 123I-FP-CIT JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 222 OP 228 DO 10.2967/jnmt.112.111617 VO 40 IS 4 A1 Eunkyung Park YR 2012 UL http://tech.snmjournals.org/content/40/4/222.abstract AB 123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (123I-FP-CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP-CIT is a radioligand for brain dopamine transporter (DAT) imaging that is useful for the differential diagnosis of Parkinson disease (PD) and other diseases that mimic PD. The sensitivity and specificity of 123I-FP-CIT SPECT for PD diagnosis are more than 90% and equivalent to those of other DAT SPECT methods. In the near future, the clinical indications of DAT imaging are expected to be broadened; for example, including treatment response assessment, disease progression monitoring, and early diagnosis of premotor PD in each individual patient.